絞り込み

16555

広告

Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.

著者 Vanassche T , Verhamme P , Wells PS , Segers A , Ageno W , Brekelmans MPA , Chen CZ , Cohen AT , Grosso MA , Medina AP , Mercuri MF , Winters SM , Zhang G , Weitz JI , Raskob GE , Büller HR
Thromb Res.2017 Dec 13 ; 162():7-14.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (172view , 0users)

Full Text Sources

Medical

Many patients with venous thromboembolism (VTE) are elderly, have multiple comorbidities and take several concomitant medications. Physicians may prefer warfarin over direct oral anticoagulants (DOACs) in such patients because comparative data are lacking. This analysis was designed to determine the effects of advanced age, comorbidities, and polypharmacy on the efficacy and safety of edoxaban and warfarin in patients with VTE.
PMID: 29248859 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード